NasdaqCM - Nasdaq Real Time Price
USD
Atossa Therapeutics, Inc. (ATOS)
2.3236
+0.1536
(+7.08%)
As of 11:18:54 AM EST. Market Open.
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Steven C. Quay FCAP, M.D., Ph.D.
|
Chairman, CEO & President | 1.02M | -- | 1951 |
|
Mr. Mark J. Daniel CPA
|
Chief Financial Officer | 349.34k | -- | 1977 |
|
Ms. Janet Rose Rea MSPH, RAC
|
Senior Vice President of Research & Development | -- | -- | -- |
|
Ms. Delly Behen P.H.R.
|
Senior Vice President of Business Operations | -- | -- | -- |
|
Dr. Richard Graydon M.D., Ph.D.
|
Interim Chief Medical Officer | -- | -- | -- |
Atossa Therapeutics, Inc.
448 NW Market Street
Suite 500
Seattle, WA 98107
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Corporate Governance
Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
